Document is current
Any future updates will be listed below
-
Authors
Doke, Tomohito https://orcid.org/0000-0003-1641-9351
Mukherjee, Sarmistha
Mukhi, Dhanunjay https://orcid.org/0000-0001-6179-5220
Dhillon, Poonam
Abedini, Amin
Davis, James G.
Chellappa, Karthikeyani
Chen, Beishan
Baur, Joseph A. https://orcid.org/0000-0001-8262-6549
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK098656, DK076077)
- License Information
-
More Information
Article History
Received: 10 July 2022
Accepted: 9 February 2023
First Online: 13 March 2023
Competing interests
: Work in the Susztak laboratory is supported by Gilead, GSK, Boehringer, Regeneron, Novo Nordisk, Novartis, Calico, Astra Zeneca, Genentech, Ventus and Maze Biotech. J.A.B. is consultant to Pfizer and Cytokinetics, an inventor on a patent for using NAD<sup>+</sup> precursors in liver injury and has received research funding and materials from Elysium Health and Metro International Biotech, both of which have an interest in NAD<sup>+</sup> precursors. The other authors declare no competing interests.
